|
1.
|
|
13 p, 904.0 KB |
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma : data from the AGAMENON-SEOM registry
/
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias. ISPA) ;
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martinez-Torron, Alba (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Custodio, Ana (Hospital Universitario La Paz (Madrid)) ;
Serra, Olbia (Institut Català d'Oncologia) ;
Cacho Lavin, Diego (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sauri, Tamara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
López, Flora (Hospital Universitario 12 de Octubre (Madrid)) ;
Visa, Laura (Hospital Universitario El Mar) ;
Granja, Mónica (Hospital Universitario Clínico San Carlos (Madrid)) ;
Martínez Lago, Nieves (Complejo Hospitalario Universitario de A Coruña) ;
Arrazubi, Virginia (Instituto de Investigación Sanitaria de Navarra) ;
Vidal Tocino, Rosario (Complejo Asistencial Universitario de Salamanca-IBSAL) ;
Hernandez, Raquel (Hospital Universitario de Canarias (La Laguna)) ;
Aguado, Gema (Hospital General Universitario Gregorio Marañón) ;
Cano, Juana María (Hospital General Universitario de Ciudad Real) ;
Martín Carnicero, Alfonso (Hospital San Pedro de Alcántara) ;
Mangas, Montserrat (Hospital de Galdakao (Usansolo, Biscaia)) ;
Pimentel, Paola (Hospital General Universitario Santa Lucía (Cartagena, Múrcia)) ;
Fernández Montes, Ana (Complejo Hospitalario de Orense) ;
Macias Declara, Ismael (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Longo, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ;
Ramchandani, Avinash (Hospital Universitario Insular de Gran Canaria) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Hurtado-Nuño, Alicia (Hospital Universitario Fundación Alcorcón) ;
Azkárate, Aitor (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Hernández Pérez, Carolina (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ;
Serrano, Raquel (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Gallego, Javier (Hospital General Universitario de Elche)
Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. [...]
2021 -  10.1177/17588359211019672
Therapeutic Advances in Medical Oncology, Vol. 13 (2021)
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
10 p, 384.2 KB |
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy
/
Ilson, David H. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Prokharau, Aliaksandr (Minsk City Clinical Oncology Dispensary) ;
Arkenau, Hendrik-Tobias (University College London) ;
Ghidini, Michele (Azienda Ospedaliera di Cremona) ;
Fujitani, Kazumasa (Osaka General Medical Center) ;
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ;
Beretta, Giordano D. (Humanitas Gavazzeni) ;
Mansoor, Wasat (The Christie NHS Foundation Trust (Regne Unit)) ;
Zhavrid, Edvard (Alexandrov National Cancer Centre of Belarus) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
George, Ben (Medical College of Wisconsin) ;
Catenacci, Daniel (University of Chicago) ;
McGuigan, Sandra (Taiho Oncology Inc) ;
Makris, Lukas (Stathmi Inc) ;
Doi, Toshihiko (National Cancer Center Hospital East (Japó)) ;
Shitara, Kohei (National Cancer Center Hospital East (Japó)) ;
Universitat Autònoma de Barcelona
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy. [...]
2019 - 10.1001/jamaoncol.2019.3531
JAMA Oncology, Vol. 6 (october 2019)
|
|
|
5.
|
|
|
6.
|
|
11 p, 726.2 KB |
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
/
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ;
Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ;
Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ;
Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ;
Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ;
Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ;
Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ;
Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ;
Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ;
Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 - 10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340
|
|
|
7.
|
|
11 p, 588.4 KB |
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma : results from the randomised phase III KEYNOTE-062 study
/
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Valderrama, A. (Center for Observational and Real-World Evidence, Merck) ;
Bang, Yung-Jue (Seoul National University College of Medicine) ;
Fuchs, C. S. (Yale University Cancer Center) ;
Shitara, Kohei (National Cancer Center Hospital East, Kashiwa, Japan) ;
Janjigian, Y. Y. (Memorial Sloan Kettering Cancer Center) ;
Qin, S. (PLA Cancer Centre of Nanjing Bayi Hospital) ;
Larson, T. G. (Minnesota Oncology Hematology) ;
Shankaran, V. (Seattle Cancer Care Alliance) ;
Stein, S. (Yale University Cancer Center) ;
Norquist, J. M. (Center for Observational and Real-World Evidence, Merck) ;
Kher, U. (Department of Medical Oncology, Merck) ;
Shah, S. (Department of Medical Oncology, Merck) ;
Alsina, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. [...]
2021 - 10.1016/j.esmoop.2021.100189
ESMO open, Vol. 6 (august 2021)
|
|
|
8.
|
|
8 p, 1.6 MB |
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer : a subgroup analysis from the phase 3 TAGS study
/
Mansoor, Wasat (The Christie NHS Foundation Trust) ;
Arkenau, Hendrik-Tobias (University College London) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Shitara, Kohei (National Cancer Center Hospital East) ;
Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ;
Cuffe, Sinead (St. James's Hospital ( Dublín, Irlanda)) ;
Dvorkin, Mikhail (Omsk Regional Clinical Centre of Oncology) ;
Park, David (St, Joseph Heritage Healthcare) ;
Ando, Takayuki (University of Toyama) ;
Van Den Eynde, Marc (UCL Cliniques Universitaires Saint-Luc) ;
Beretta, Giordano D. (Humanitas Gavazzeni) ;
Zaniboni, Alberto (Fondazione Poliambulanza-Istituto Ospedaliero) ;
Doi, Toshihiko (National Cancer Center Hospital East) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Ilson, David H. (Memorial Sloan Kettering Cancer Center) ;
Makris, Lukas (Stathmi, Inc, New Hope, PA USA) ;
Benhadji, Karim A. (Taiho Oncology) ;
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Universitat Autònoma de Barcelona
Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. [...]
2021 - 10.1007/s10120-021-01156-x
Gastric Cancer, Vol. 24 (march 2021) , p. 970-977
|
|
|
9.
|
|
12 p, 1.7 MB |
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
/
Kirschbrown, Whitney. P. (Clinical Pharmacology. Genentech Research and Early Development) ;
Wang, B. (Clinical Pharmacology. Genentech Research and Early Development) ;
Nijem, I. (Clinical Pharmacology. Genentech Research and Early Development) ;
Ohtsu, A. (Department of Gastrointestinal Oncology. National Cancer Center Hospital East) ;
Hoff, P. M. (Instituto do Câncer de São Paulo. Faculdade de Medicina da Universidade de São Paulo) ;
Shah, M. A. (Medical Oncology/Solid Tumor Program. Sandra and Edward Meyer Cancer Center. Weill Cornell Medical College) ;
Shen, L. (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing). Department of Gastrointestinal Oncology. Peking University Cancer Hospital and Institute) ;
Kang, Y. K. (Department of Oncology. Asan Medical Center. University of Ulsan College of Medicine) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Girish, S. (Clinical Pharmacology. Genentech Research and Early Development) ;
Garg, Amit (Clinical Pharmacology. Genentech Research and Early Development) ;
Universitat Autònoma de Barcelona
Purpose: To characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the pertuzumab regimen in these patients. [...]
2019 - 10.1007/s00280-019-03871-w
Cancer Chemotherapy and Pharmacology, Vol. 84 Núm. 3 (january 2019) , p. 539-550
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
